Ascendis Pharma reports promising phase III data

The company has shown statistical significance for Transcon PTH as a treatment for hypoparathyroidism.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by christian bundgaard, translated by catherine brett

Ascendis Pharma has released the final phase III data from its clinical studies of candidate Transcon PTH as a treatment for hypoparathyroidism, which causes cramps and muscle spasms due to low levels of calcium and PTH.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading